Press Releases Aura Biosciences, Inc.

Equities

AURA

US05153U1079

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
7.13 ^USD	+4.70%		+1.13%	-19.53%

29/05	Transcript : Aura Biosciences, Inc. - Special Call
09/05	Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aura Biosciences : Corporate Presentation June 2024	05/06	PU
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference	31/05	AQ
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024	23/05	AQ
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights	09/05	AQ
Aura Biosciences to Participate in Upcoming Investor Conferences	08/05	AQ
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/03	BU
Aura Biosciences to Participate in Upcoming Investor Conferences	26/02	BU
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan for First-Line Treatment of Early-Stage Choroidal Melanoma	08/12	AQ
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07/12	BU
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights	10/11	BU
Aura Biosciences to Participate in Upcoming Investor Conferences	08/11	BU
Aura Biosciences Announces Pricing of Public Offering of Common Stock	07/11	BU
Aura Biosciences Announces Proposed Public Offering of Common Stock	07/11	BU
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma	07/11	BU
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma	01/11	AQ
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023	01/23/01	BU
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09/23/09	AQ
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments	03/23/03	BU
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights	09/23/09	BU
AURA BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	08/23/08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aura Biosciences, Inc.

Equities

AURA

US05153U1079

Press Releases

Filters